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The key metabolic regulator, AMP-activated protein kinase (AMPK), is reported to be
down-regulated in metabolic disorders, but the mechanisms are poorly characterised.
Recent studies have identiﬁed phosphorylation of the AMPKα1/α2 catalytic subunit iso-
forms at Ser487/491, respectively, as an inhibitory regulation mechanism. Vascular endo-
thelial growth factor (VEGF) stimulates AMPK and protein kinase B (Akt) in cultured
human endothelial cells. As Akt has been demonstrated to be an AMPKα1 Ser487
kinase, the effect of VEGF on inhibitory AMPK phosphorylation in cultured primary
human endothelial cells was examined. Stimulation of endothelial cells with VEGF rapidly
increased AMPKα1 Ser487 phosphorylation in an Akt-independent manner, without alter-
ing AMPKα2 Ser491 phosphorylation. In contrast, VEGF-stimulated AMPKα1 Ser487
phosphorylation was sensitive to inhibitors of protein kinase C (PKC) and PKC activation
using phorbol esters or overexpression of PKC-stimulated AMPKα1 Ser487 phosphoryl-
ation. Puriﬁed PKC and Akt both phosphorylated AMPKα1 Ser487 in vitro with similar
efﬁciency. PKC activation was associated with reduced AMPK activity, as inhibition of
PKC increased AMPK activity and phorbol esters inhibited AMPK, an effect lost in cells
expressing mutant AMPKα1 Ser487Ala. Consistent with a pathophysiological role for this
modiﬁcation, AMPKα1 Ser487 phosphorylation was inversely correlated with insulin sen-
sitivity in human muscle. These data indicate a novel regulatory role of PKC to inhibit
AMPKα1 in human cells. As PKC activation is associated with insulin resistance and
obesity, PKC may underlie the reduced AMPK activity reported in response to overnutrition
in insulin-resistant metabolic and vascular tissues.
Introduction
AMP-activated protein kinase (AMPK) is a heterotrimeric Ser/Thr kinase consisting of catalytic (α)
and regulatory (β and γ) subunits that acts as a key sensor of cellular and whole-body energy status
[1,2]. Binding of AMP to the γ-subunit allosterically activates AMPK, promotes activating phosphoryl-
ation of AMPKα at Thr172 by the ubiquitous upstream AMPK kinase LKB1 (liver kinase B1) and
inhibits Thr172 dephosphorylation, effects that are competitively inhibited by ATP [1,2]. As a conse-
quence, AMPK is activated by conditions that increase the AMP:ATP ratio, such as hypoxia, hypogly-
caemia, ischaemia and skeletal muscle contraction [1–3]. Furthermore, several pharmacological agents
and xenobiotics, such as metformin, resveratrol and berberine, have been demonstrated to activate
AMPK by inhibiting mitochondrial ATP synthesis and thereby increasing AMP:ATP [4]. AMPK can
also be activated independent of changes in adenine nucleotide ratios by increasing intracellular Ca2+,
in cells that express the alternative Thr172 kinase CaMKKβ (Ca2+/calmodulin-dependent protein
kinase kinase-β) [5]. Once activated, AMPK serves to stimulate ATP synthesis and suppress ATP util-
isation by multiple effects on nutrient metabolism, including the stimulation of fatty acid oxidation,
muscle glucose uptake and mitochondrial biogenesis in addition to the inhibition of protein
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translation, fatty acid synthesis, lipogenesis and cholesterol synthesis. As a consequence, AMPK activation
serves to normalise cellular adenine nucleotide ratios. Owing to these effects on nutrient metabolism, activation
of AMPK has been proposed to be a therapeutic target for metabolic diseases, including diabetes and obesity
[1–3]. Furthermore, AMPK has been demonstrated to have anti-inﬂammatory, anti-proliferative and anti-
atherosclerotic actions, suggesting that it may be a useful therapeutic target in macrovascular disease, inﬂamma-
tory diseases and cancer [6,7].
Despite the well-characterised mechanisms by which AMPK is activated, far less is known concerning the
mechanisms that down-regulate AMPK activity, such as that reported in obese, insulin-resistant rodents and
humans [8–11]. Recently, phosphorylation of AMPKα1/α2 at Ser487/491 (human sequence, equivalent to
rodent Ser485/491) has been reported to inhibit AMPK activity [12–18]. Several studies have demonstrated that
Akt phosphorylates AMPKα1 Ser487 in response to insulin or IGF-1 (insulin-like growth factor) in heart, adi-
pocytes, vascular smooth muscle cells (VSMCs) and tumour cell lines [13–17]. Phosphorylation of AMPKα1
Ser487 by Akt inhibits Thr172 phosphorylation and thereby reduces AMPK activity [13,17]. Recombinant PKA
(cAMP-dependent protein kinase) also phosphorylates AMPKα1 Ser487 in vitro, and cAMP-elevating agents
have also been reported to stimulate AMPKα1 Ser487 phosphorylation in mouse embryonic ﬁbroblasts and
insulin-secreting cell lines [19,20]. Recently, inhibitors of the mitogen-activated protein kinase kinase
(MEK1/2) extracellular signal-regulated kinase 1/2 (ERK1/2) and IKK (inhibitor of nuclear factor-κB kinase)
pathways have also been reported to attenuate AMPKα1 Ser487 phosphorylation in human dendritic cells and
a mouse macrophage cell line, implicating these pathways as regulators of AMPKα1 Ser487 [21,22].
In contrast, AMPKα2 Ser491 has been reported to be a poor substrate for Akt in vitro [17], although p70S6
kinase, downstream from Akt, has been reported to underlie leptin-mediated phosphorylation of AMPKα2
Ser491 in the mouse hypothalamus and a neuronal cell line [23]. Using an antibody that recognises both
AMPKα1/α2 Ser487/491 phosphorylation, AMPK autophosphorylation at Ser487/491 has been reported
in vitro [13] and the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) has been
reported to stimulate AMPKα1/α2 Ser487/491 phosphorylation in neonatal rat cardiomyocytes, rat VSMCs and
a mouse microglial cell line [24–26].
Intriguingly, aortae from mice with experimental diabetes exhibit increased basal and IGF-1-stimulated phos-
phorylation of Akt and AMPKα1 Ser487, with concomitant reduced AMPKα Thr172 phosphorylation [15],
and infusion of rats with glucose increased AMPKα1/α2 Ser487/491 phosphorylation [27]. Furthermore, trans-
fection of a murine muscle cell line with AMPKα2 Ser491Ala has been recently reported to attenuate the inhib-
ition of insulin signalling by phorbol 12-myristate 13-acetate (PMA) [18]. These studies suggest that increased
AMPKα1/α2 Ser487/491 phosphorylation may underlie the reduced AMPK activity reported in insulin-
resistant states [18,27]. Despite this, the AMPKα1/α2 Ser487/491 phosphorylation status in human insulin
resistance has not been reported.
We have previously demonstrated that vascular endothelial growth factor (VEGF) stimulates AMPK in a
CaMKK-dependent manner in human endothelial cells [28]. VEGF receptor activation in endothelial cells also
stimulates Akt and ERK1/2 activity, suggesting that VEGF may be an endogenous AMPK activator that concur-
rently stimulates activating phosphorylation at Thr172 and inhibitory phosphorylation at Ser487. The present
study aimed to examine whether VEGF promotes inhibitory AMPK phosphorylation in cultured primary
human endothelial cells and deﬁne the mechanisms underlying this.
Materials and methods
Materials
Cryopreserved human aortic endothelial cells (HAECs), human umbilical vein endothelial cells (HUVECs) and
MV2 medium were purchased from Promocell (Heidelberg, Germany). VEGF, oleoyl-2-acetyl-sn-glycerol (OAG)
and mouse anti-FLAG tag antibodies were obtained from Sigma–Aldrich (Poole, U.K.). STO-609, CRT0066101,
LY333531 and GF109203X were from Tocris (Abingdon, U.K.). A769662 and mouse anti-β-tubulin antibodies
were obtained from Abcam (Cambridge, U.K.). AICAR was from Toronto Research Chemicals (Toronto, Canada).
Wortmannin, PMA, Akt inhibitor VIII (Akti-1/2) and agarose-conjugated mouse anti-myc tag antibodies were
obtained from Merck Millipore (Watford, U.K.). Calf intestinal alkaline phosphatase (CIAP) was from Promega
(Southampton, U.K.). Opti-MEM reduced serum medium was from Life Technologies (Paisley, U.K.). HiPerFect
and siRNA targeted to PKC isoforms were obtained from Qiagen (Manchester, U.K.). Rabbit anti-phospho-ACC
(acetyl-CoA carboxylase; Ser79), anti-AMPKα2, anti-phospho-AMPKα (Thr172), anti-phospho-AMPKα1
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(Ser485), anti-phospho-AMPKα1/α2 (Ser485/Ser491), anti-phospho-Akt (Ser473), anti-ERK1/2,
anti-phospho-MARCKS (myristoylated alanine-rich PKC substrate; Ser152/Ser156), anti-protein kinase C (PKC)α,
anti-PKCζ, anti-phospho-protein kinase D (PKD)/PKCm (Ser916), anti-PKD/PKCm antibodies and mouse
anti-Akt, anti-phospho-ERK1/2 (Thr202/Tyr204) antibodies were from New England Biolabs UK (Hitchin, U.K.).
Rabbit anti-PKC (pan), anti-PKCη and anti-PKCβ1 antibodies were from Santa Cruz Biotechnology, Inc. (Dallas,
TX, U.S.A.). Mouse anti-PKCγ, anti-PKCδ, anti-PKCε, anti-PKCθ and anti-PKCλ antibodies were from BD
Transduction Laboratories (Oxford, U.K.). IRdye680- or 800-labelled donkey anti-mouse IgG and anti-rabbit IgG
antibodies were from LiCor Biosciences (Lincoln, U.K.). Lipofectamine 2000, Medium 199, mouse anti-GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) and Alexa Fluor 680 donkey anti-sheep IgG antibodies were from
Life Technologies (Paisley, U.K.). Puriﬁed rat brain PKC was obtained from Promega (Manchester, U.K.). Puriﬁed
human recombinant Akt1 was obtained from Biafﬁn GmbH (Kassel, Germany). Phosphatidylserine (PtdSer) was
from Sigma–Aldrich (Poole, U.K.). Sheep anti-AMPKα1 and anti-AMPKα2 antibodies [29] and plasmids
(pcDNA5/FRT) expressing FLAG-tagged AMPKα1, AMPKα1 Ser487Ala, AMPKα2 or AMPKα2 Ser491Ala [17]
were a generous gift from Prof. D.G. Hardie (University of Dundee, U.K.). HeLa cells stably expressing wild-type
LKB1 have been described elsewhere [30] and were kindly provided by Prof. D. Alessi (University of Dundee, U.
K.). Plasmids (pBΔG) expressing full-length bovine PKCα, human PKCβ1 and human PKCβ2 have been
described previously [31]. SV40-immortalised mouse embryonic ﬁbroblasts (MEFs) lacking AMPKα1 and
AMPKα2 have been described elsewhere [32] and were kindly provided by Dr. B. Viollet (Institut Cochin, Paris,
France). All other reagents were from sources described previously [33–35].
Cell culture
HAECs and HUVECs were grown in MV2 medium (Promocell, Heidelberg, Germany) and passaged when at
80% conﬂuence. Cells were used for experiments between passages 3 and 6 as described previously [33–35].
For experiments in which extracellular Ca2+ was depleted, cells were incubated in KRH buffer [20 mmol/l
HEPES–NaOH (pH 7.4), 119 mmol/l NaCl, 5 mmol/l NaHCO3, 5 mmol/l glucose, 4.8 mmol/l KCl, 1.2 mmol/l
MgSO4, 1.2 mmol/l NaH2PO4, 2.5 mmol/l CaCl2] or KRH without CaCl2 supplemented with 1 mmol/l EGTA
for 2 h prior to stimulation with VEGF or AICAR. HeLa cells and HEK293 cells were cultured in DMEM sup-
plemented with 10% (v/v) foetal calf serum (FCS). HeLa cells stably expressing LKB1 and MEFs lacking
AMPKα1 and AMPKα2 (AMPK KO MEFs) were cultured as described previously [32,35].
Transient transfection of AMPK KO MEFs, HeLa cells or HEK293 cells
AMPK KO MEFs (∼60% conﬂuence), HeLa cells or HEK293 cells (∼80% conﬂuence) in six-well plates were
incubated in 1 ml/well Opti-MEM. DNA–Lipofectamine 2000 complexes [150 ml of 13 mg/ml plasmid DNA,
2.5% (v/v) Lipofectamine 2000 for AMPK KO MEFs; 400 ml of 5 mg/ml plasmid DNA, 0.5% (v/v)
Lipofectamine 2000 for HeLa cells; 150 ml of 13 mg/ml plasmid DNA, 3.3% (v/v) Lipofectamine 2000 for
HEK293 cells] were added dropwise to each well. Cells were incubated at 37°C for 2 h (AMPK KO MEFs) or
4 h (HeLa and HEK cells) before the transfection media were replaced with 2 ml/well complete culture media.
After incubation overnight, medium was replaced with serum-free DMEM for 2 h and cell lysates were
prepared.
siRNA-mediated down-regulation of PKC isoforms in HUVECs
Cells at ∼70% conﬂuence in six-well plates were incubated in 750 ml/well Opti-MEM and 150 ml of 3.2 mmol/l
siRNA complexed with 8% (v/v) HiPerFect in Opti-MEM were added dropwise to each well. Cells were incu-
bated at 37°C for 3 h prior to the addition of 1.5 ml/well MV2 medium. After further incubation for 48 h at
37°C, medium was replaced with Medium 199 for 2 h prior to stimulation in the presence or absence of VEGF
(10 ng/ml, 5 min).
Preparation of cell lysates, SDS–PAGE and immunoblotting
Cell lysates were prepared; proteins were resolved by SDS–PAGE and subjected to immunoblotting with the
antibodies indicated as described previously [33–35]. Proteins were visualised using infrared dye-labelled sec-
ondary antibodies on a LiCor Odyssey infrared imaging system and analysed using Image J software.
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Immunoprecipitation and assay of AMPK activity
Cell lysates (0.1 mg) were added to 1 μg of sheep anti-AMPKα1 or AMPKα2 antibodies bound to Protein G
Sepharose (5 μl packed volume/immunoprecipitation) in IP buffer [50 mmol/l Tris–HCl (pH 7.4 at 4°C),
150 mmol/l NaCl, 50 mmol/l NaF, 5 mmol/l Na4P2O7, 1 mmol/l Na3VO4, 1 mmol/l EDTA, 1 mmol/l EGTA,
1 mmol/l DTT, 0.1 mmol/l benzamidine, 0.1 mmol/l phenylmethylsulphonyl ﬂuoride, 5 μg/ml soybean trypsin
inhibitor, 1% (v/v) Triton X-100, 1% (v/v) glycerol] and mixed for 3 h at 4°C. Immunodepleted lysates were
collected and immunoprecipitates were washed with high-salt IP buffer (IP buffer containing 1 mol/l NaCl, 2 ×
1 ml), IP buffer (2 × 1 ml) and 1 × 1 ml HBD buffer [50 mmol/l HEPES–NaOH (pH 7.4), 0.02% (v/v) Brij-35
and 1 mmol/l DTT]. Immunoprecipitates and immunodepleted lysates were subjected to SDS–PAGE and
immunoblotting or assayed for AMPK activity using the SAMS substrate peptide as described previously [33].
Immunoprecipitation and in vitro phosphorylation of AMPK
HEK293 cells were infected with adenoviruses expressing a myc-tagged kinase dead AMPKα1 [36] as described
previously [33,35] or transiently transfected with FLAG-tagged AMPKα1, AMPKα1 Ser487Ala, AMPKα2 or
AMPKα2 Ser491Ala and cell lysates were prepared. Kinase-dead AMPK was immunoprecipitated with agarose-
conjugated mouse anti-myc tag antibodies. FLAG-tagged AMPK was immunoprecipitated with mouse
anti-FLAG antibodies. Immunoprecipitates were incubated with 100 U/ml CIAP for 30 min at 30°C and
washed three times each with IP buffer and HEPES–DTT buffer [50 mmol/l HEPES (pH 7.4) and 1 mmol/l
DTT] prior to incubation in the presence or absence of 0.02 or 0.1 U of PKC (active rat brain) or Akt1
(human recombinant), 1.7 mmol/l Ca2+, 0.6 mg/ml PtdSer [prepared by sonication (1 h, 50°C) in HEPES–DTT
buffer] and 0.2 mmol/l ATP, 6 mmol/l MgCl2 for 30 min at 30°C. AMPK immunoprecipitates were centrifuged
and the resultant pellets were washed with IP buffer and HEPES–DTT buffer prior to SDS–PAGE and
immunoblotting.
Human muscle samples
Particulate membrane fractions from muscle (vastus lateralis) biopsy lysates were prepared in an earlier study
[37], from volunteers of European descent in which the insulin sensitivity index (ISI) derived by Matsuda and
DeFronzo [38] was also calculated. Fractions from six individuals were chosen for analysis due to their range of
ISI and availability. Muscle biopsy lysates were obtained with informed consent from individuals with ethical
approval for these analyses obtained from the National Research Ethics Service (Proportionate Review
Sub-committee of the NRES Committee West Midlands — Solihull).
Statistics
Statistically signiﬁcant differences were determined using a two-tailed Student’s t-test or ANOVA as appropri-
ate, with P < 0.05 deemed signiﬁcant.
Results
VEGF stimulates AMPKα1 Ser487 phosphorylation in human endothelial cells in
a manner dependent on extracellular Ca2+ but independent of Akt or ERK1/2
Stimulation of HAECs with 10 ng/ml VEGF rapidly stimulated phosphorylation of AMPKα Thr172, reaching a
maximum after 5 min, before returning to basal levels by 20 min (Figure 1A,B). Both AMPKα1 and AMPKα2
isoforms are present in HAECs, but complexes containing AMPKα1 account for almost all of the basal and
VEGF-stimulated AMPK activity in whole cell lysates (Supplementary Figure S1A,B). VEGF stimulated a signiﬁ-
cant increase in phosphorylation when using antibodies that recognise AMPKα1 Ser487 alone or both AMPKα1/
α2 Ser487/491, which reached a maximum between 5 and 10 min before returning to basal levels by 30 min
(Figure 1A,B). VEGF also stimulated AMPKα1 Ser487 in HUVECs with similar kinetics (Supplementary
Figure S1C). VEGF rapidly stimulated AMPK activity within 2 min, reaching a maximum after 5 min before
returning to basal levels (Figure 1C). To determine the kinase responsible for regulating VEGF-stimulated
AMPKα Ser487/491 phosphorylation, selective kinase inhibitors were used. Pre-incubation of HAECs with the
Akt inhibitor Akti-1/2 (Akt inhibitor VIII) or the MEK1/2 inhibitor PD184352 had no effect on
VEGF-stimulated AMPKα Ser487/491 phosphorylation, despite completely inhibiting Akt Ser473 and ERK1/2
Thr202/Tyr204 phosphorylation, respectively (Figure 1D). Supporting the Akt-independent phosphorylation of
AMPKα Ser487/491, stimulation of HAECs with insulin robustly stimulated Akt, but had no effect on AMPKα1
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Ser487 phosphorylation (Supplementary Figure S1D). Furthermore, the phosphatidylinositide-30-kinase (PI3K)
inhibitor, wortmannin, completely inhibited VEGF-stimulated Akt Ser473 phosphorylation, without affecting
VEGF-stimulated AMPKα1 Ser487 phosphorylation (Supplementary Figure S1E–G).
We have previously demonstrated that VEGF-stimulated Thr172 phosphorylation is mediated by CaMKK
[28,33] and autophosphorylation of Ser487 by AMPK has been reported in vitro [13]. We therefore examined
whether VEGF-stimulated Ser487 phosphorylation was sensitive to CaMKK inhibition. Pre-incubation of
HAECs with the CaMKK inhibitor STO-609 signiﬁcantly inhibited VEGF-stimulated AMPKα Thr172 phos-
phorylation, without inﬂuencing Thr172 phosphorylation stimulated by the CaMKK-independent AMPK activa-
tor, AICAR, demonstrating that STO-609 does not inhibit AMPK directly in these experiments (Figure 2A,B). In
Figure 1. VEGF stimulates AMPK Ser487/491 phosphorylation independent of Akt or ERK1/2.
HAECs were incubated (A–C) in 10 ng/ml VEGF for the times indicated and lysates were prepared. (A and B) Proteins were
resolved by SDS–PAGE and immunoblotted with the antibodies indicated, or (C) AMPK was immunoprecipitated and activity
was assayed. (D) HAECs were pre-incubated in the presence or absence of 1 mmol/l Akti1/2 or PD184352 for 60 min prior to
VEGF stimulation (10 ng/ml, for the times indicated), lysates were prepared and proteins were resolved by SDS–PAGE and
immunoblotted with the antibodies indicated. (A and D) Representative immunoblots are shown, repeated on two further
occasions with similar results. (B) Densitometric quantiﬁcation of immunoblots from 3 to 5 independent experiments (mean ±
SEM). (C) AMPK activity (mean ± SEM). *P < 0.05, **P < 0.01, ***P < 0.005 relative to the absence of VEGF.
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contrast, inhibition of CaMKK activity had no effect on VEGF-stimulated AMPKα1 Ser487 phosphorylation,
arguing against VEGF-stimulated autophosphorylation of Ser487 (Figure 2A,C). Intriguingly, AICAR also stimu-
lated AMPKα1 Ser487 phosphorylation in a CaMKK-independent manner in HAECs (Figure 2A,C). STO-609
inhibited VEGF-stimulated AMPK activity, but was without effect on AICAR-stimulated AMPK activity
(Figure 2D). To determine whether increases in intracellular Ca2+ concentrations were important in
VEGF-stimulated Ser487 phosphorylation, HAECs were incubated in the absence of extracellular Ca2+
and VEGF-stimulated Ser487 phosphorylation was assessed. Depletion of extracellular Ca2+ signiﬁcantly inhib-
ited VEGF-stimulated phosphorylation of AMPKα at Thr172 and Ser487, but had no effect on
AICAR-stimulated phosphorylation of AMPK at these sites (Figure 2E–G). Depletion of Ca2+ inhibited
VEGF-stimulated AMPK activity, but was without effect on AICAR-stimulated AMPK activity, in agreement
with levels of Thr172 phosphorylation (Figure 2H).
VEGF stimulates AMPKα1 Ser487 phosphorylation in a PKC-dependent
manner
VEGF stimulates numerous signalling pathways including the PKC family of kinases. As the conventional PKC
isoforms (cPKC — α, β1/2 and γ) require Ca2+ for activation, we determined the effect of selective PKC inhibi-
tors on VEGF-stimulated AMPK phosphorylation and activity. Pre-incubation of HUVECs with either
GF109203X (cPKC-selective) or LY333531 (PKCβ-selective) completely inhibited VEGF-stimulated AMPKα1
Ser487 phosphorylation, without signiﬁcantly altering VEGF-stimulated AMPKα Thr172 phosphorylation
(Figure 3A–C). Furthermore, incubation of HAECs with either GF109203X or LY333531 signiﬁcantly stimu-
lated basal AMPK activity and tended to increase VEGF-stimulated AMPK activity (Figure 3D,E). To deter-
mine whether either PKC inhibitor directly inﬂuenced AMPK activity, immunoprecipitated AMPK was
incubated with either GF109203X or LY333531 and AMPK activity was assessed. Neither GF109203X nor
LY333531 had any signiﬁcant direct effect on basal or AMP-stimulated AMPK activity in vitro, unlike the
AMPK inhibitor, compound C (Supplementary Figure S2).
PKC activators stimulate AMPKα1 Ser487 phosphorylation
Supporting the potential role of PKC as an AMPKα1 Ser487 kinase, the synthetic PKC activator PMA rapidly
stimulated phosphorylation of both the PKC substrate MARCKS and AMPKα1 Ser487 (Figure 4A).
Furthermore, immunoprecipitation of AMPK complexes containing AMPKα1 or AMPKα2 from HUVECs sti-
mulated with PMA or the diacylglycerol mimetic OAG demonstrated that both PMA and OAG stimulate
AMPKα1 Ser487 phosphorylation (Figure 4B). In contrast, no immunoreactive bands were observed with an
antibody that recognises both AMPKα1 Ser487 and AMPKα2 Ser491 in AMPKα2 immunoprecipitates or
AMPKα1 immunodepleted lysates from PMA- or OAG-stimulated HUVECs, indicating that PKC activators
stimulate AMPKα1 Ser487 and not AMPKα2 Ser491 phosphorylation (Figure 4B). In agreement with an
inhibitory role of Ser487 phosphorylation, PMA inhibited AMPK activity in HUVECs by 31 ± 5% (Figure 4C).
To determine whether the inhibition of AMPK activity by PMA was mediated by phosphorylation of Ser487,
AMPKα KO MEFs were transfected with FLAG-tagged AMPKα1 or AMPKα1 in which Ser487 had been
mutated to Ala and stimulated with PMA. PMA inhibited AMPK activity in cells expressing wild-type
AMPKα1 by 31 ± 11%, yet had no effect in cells expressing AMPKα1 Ser487Ala (Figure 4C). Efﬁciency of
transfection was similar for expression of FLAG-tagged wild-type or Ser487Ala mutant AMPKα1
(Supplementary Figure S3). To compare the sensitivity of VEGF- and PMA-stimulated AMPKα1 Ser487 phos-
phorylation with PKC inhibition, HUVECs were incubated with increasing concentrations of the
PKCβ-selective inhibitor LY333531 prior to stimulation with VEGF or PMA. PMA (1 mmol/l) stimulated phos-
phorylation of both AMPKα1 Ser487 and the PKC substrate MARCKS to a greater extent than VEGF (10 ng/
ml) (Figure 4D). The concentration dependence of LY333531-mediated inhibition of VEGF-stimulated phos-
phorylation of AMPKα1 Ser487 and MARCKS was almost identical, with an IC50 of ∼0.1–0.15 μmol/l
(Figure 4E). In contrast, the concentration dependence of LY333531-mediated inhibition of PMA-stimulated
phosphorylation of AMPKα1 Ser487 and MARCKS was different, whereby the IC50 for inhibition of AMPKα1
Ser487 was similar to VEGF-stimulated cells (∼0.1 μmol/l), but the IC50 for inhibition of MARCKS phosphor-
ylation was greater (∼0.4 μmol/l; Figure 4F).
PMA-mediated phosphorylation of AMPKα1 Ser487 was not limited to endothelial cells, as PMA stimulated
AMPKα1 Ser487 phosphorylation and MARCKS phosphorylation in HeLa cells, without signiﬁcantly altering
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Figure 2. VEGF-stimulated AMPKα1 Ser487 phosphorylation is sensitive to Ca2+ removal but insensitive to CaMKK
inhibition.
HAECs were (A–D) incubated in the presence or absence of 10 mmol/l STO-609 for 60 min or (E–H) presence or absence of
extracellular Ca2+ for 60 min, prior to stimulation with VEGF (10 ng/ml, 5 min) or AICAR (2 mmol/l, 45 min). HAEC lysates were
prepared; (A–C and E–G) proteins were resolved by SDS–PAGE and immunoblotted with the antibodies indicated or (D and H)
AMPK was assayed. (A and E) Representative immunoblots are shown, repeated with similar results on two further occasions.
Densitometric quantiﬁcation of (B and F) AMPK Thr172 and (C and G) AMPKα1 Ser487 phosphorylation (mean ± SEM) from
three or four independent experiments. (D and H) AMPK activity (mean ± SEM) from three independent experiments. *P < 0.05,
**P < 0.01 relative to the absence of STO-609 or the presence of extracellular Ca2+.
© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4687
Biochemical Journal (2016) 473 4681–4697
DOI: 10.1042/BCJ20160211
basal phosphorylation of the AMPK substrate, ACC. Pre-incubation with STO-609 reduced ACC phosphoryl-
ation in the presence or absence of PMA, but had no effect on PMA-stimulated AMPKα1 Ser487 or MARCKS
phosphorylation (Supplementary Figure S4). In HeLa cells stably expressing LKB1, PMA stimulated AMPKα1
Ser487 phosphorylation and concomitantly inhibited basal and AICAR-stimulated ACC phosphorylation.
AICAR had no effect on basal or PMA-stimulated AMPKα1 Ser487 phosphorylation in these cells
(Supplementary Figure S4).
Chronic treatment of cells with PMA has been shown to down-regulate levels of PKC by stimulating its deg-
radation [39]. To further investigate the role of PKC in the regulation of AMPKα1 Ser487 phosphorylation,
HUVECs were incubated overnight with 200 nmol/l PMA prior to acute stimulation with VEGF, AICAR, the
AMP-independent AMPK activator A769662 or OAG. Neither PKCβ nor immunoreactivity using a pan-speciﬁc
Figure 3. PKC inhibitors ablate VEGF-stimulated AMPKα1 Ser487 phosphorylation and stimulate AMPK activity.
(A–C) HUVECs were pre-incubated in the presence or absence of either 1 μmol/l GF109203X (GFX) or LY333531 (LY3) for 1 h
prior to stimulation with VEGF (10 ng/ml, 5 min). Cell lysates were prepared, proteins were resolved by SDS–PAGE and
immunoblotted with the antibodies indicated. (D and E) HAECs were pre-incubated in the presence or absence of 1 μmol/l GFX
or LY3 for 1 h prior to stimulation with VEGF (10 ng/ml, 10 min) and lysates were prepared. AMPK was immunoprecipitated
from HAEC lystaes and assayed for AMPK activity. (A) Representative immunoblots are shown, repeated with similar results on
two further occasions. (B and C) Densitometric quantiﬁcation of immunoblots. Data are expressed as mean ± SEM relative to
VEGF-treated HUVECs in the absence of inhibitor from three independent experiments. (D and E) Data represent mean ± SEM
AMPK activity from eight and three independent experiments, respectively. †P < 0.05, ††P < 0.01 relative to the absence of
VEGF, **P < 0.01, ***P < 0.001 relative to the absence of PKC inhibitor.
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anti-PKC antibody was detectable after chronic PMA treatment (Figure 5A). Chronic PMA treatment also
down-regulated PKCα, PKCγ, PKCη, PKCθ and PKCμ in both HUVECs and HAECs (Supplementary
Figure S5). PKCδ was unaffected by chronic PMA treatment, whereas PKCε, PKCζ and PKCλ were undetectable
in HUVECs or HAECs (Supplementary Figure S5). Chronic PMA treatment completely inhibited the rapid
phosphorylation of AMPKα1 Ser487 and MARCKS in response to VEGF or OAG (Figure 5A,B). AICAR did
not stimulate MARCKS phosphorylation and AICAR-stimulated AMPKα1 Ser487 phosphorylation was
unaffected by chronic PMA treatment (Figure 5A). The direct AMPK activator A769662 did not inﬂuence
Figure 4. PKC activators stimulate AMPKα1 Ser487 phosphorylation.
(A) HUVECs were stimulated with PMA (1 mmol/l) for the indicated durations and lysates prepared. Lysates were resolved by
SDS–PAGE and immunoblotted using the antibodies indicated. (B) HUVECs were stimulated with PMA (1 μmol/l, 20 min) or
OAG (0.1 mmol/l, 20 min), and lysates were prepared. AMPK complexes were immunoprecipitated with anti-AMPK α1 or α2
antibodies, and the pellets (P) and immunodepleted lysates (ID) were analysed by immunoblotting with the antibodies
indicated. (C) AMPK KO MEFs were transiently transfected with AMPKα1 (wild type, WT) or AMPKα1 Ser487Ala. HUVECs or
transfected MEFs were stimulated with PMA (1 μmol/l, 20 min) and lysates were prepared. AMPK activity was assessed in
immunoprecipitates. (D) HUVECs were pre-treated with the indicated concentrations of LY333531 for 1 h prior to stimulation
with VEGF (10 ng/ml, 5 min) or PMA (1 mmol/l, 20 min). Cell lysates were prepared and analysed by immunoblotting with the
antibodies indicated. (A, B and D) Representative immunoblots are shown, repeated with similar results on two, one and two
further occasions, respectively. (C) AMPK activity *P < 0.05, **P < 0.01 relative to the absence of PMA. (E and F) Densitometric
quantiﬁcation (mean ± SEM) of immunoblots in (D). Data are expressed relative to (E) VEGF-treated or (F) PMA-treated HUVECs
in the absence of inhibitor from three independent experiments.
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AMPKα1 Ser487 or MARCKS phosphorylation (Figure 5A). Despite reducing AMPKα1 Ser487 phosphoryl-
ation, chronic PMA treatment did not signiﬁcantly alter AMPK activity under basal or VEGF/AICAR/
A769662-stimulated conditions (Figure 5C).
Up-regulation of PKC expression stimulates AMPKα1 Ser487 phosphorylation
Overexpression of bovine PKCα or human PKCβ1 in HeLa cells signiﬁcantly increased AMPKα1 Ser487 phos-
phorylation. In contrast, overexpression of PKCβ2 tended to increase AMPKα1 Ser487 phosphorylation, yet
this did not achieve statistical signiﬁcance (Figure 6A,B). Overexpression of PKCβ1 and PKCβ2 tended to
reduce basal ACC phosphorylation (Figure 6A,C). Furthermore, puriﬁed PKC phosphorylated kinase inactive
AMPKα1 in vitro in the presence of PtdSer and Ca2+, with similar efﬁciency to a comparable activity of Akt
(Figure 6D,E). PKC did not increase anti-phospho-AMPK Ser487 immunoreactivity of AMPKα1 in which
Ser487 had been mutated to Ala in vitro (Supplementary Figure S6A). Speciﬁc siRNA-mediated down-
regulation of PKCα also substantially down-regulated PKCβ1 levels, yet this was not associated with reduced
VEGF-stimulated AMPKα1 Ser487 phosphorylation in HUVECs (Supplementary Figure S6B,C).
Inhibition of PKCm does not ablate VEGF-stimulated AMPKα1 Ser487
phosphorylation
While this manuscript was in preparation, it was reported that PKD1 (the mouse orthologue of human PKCμ)
phosphorylates AMPKα2 Ser491 in vitro with similar efﬁciency to Akt and that PMA stimulated AMPKα2
Ser491 in a mouse muscle cell line in a PKD1-dependent manner [18]. VEGF markedly increased PKCm
Ser916 phosphorylation in HAECs, an autophosphorylation site that correlates with PKCm activity [40], and
this was entirely blocked by the PKCm inhibitor CRT0066101 (Figure 7). Pre-incubation with CRT0066101
tended to inhibit VEGF-stimulated AMPKα1 Ser487 phosphorylation, although this effect did not achieve stat-
istical signiﬁcance and completely inhibited VEGF-stimulated ACC phosphorylation without inhibiting
VEGF-stimulated AMPK activity (Figure 7). Speciﬁc siRNA-mediated down-regulation of PKCm had no effect
on VEGF-stimulated AMPKα1 Ser487 phosphorylation in HUVECs (Supplementary Figure S5C).
AMPKα1 Ser487 phosphorylation is inversely associated with insulin
sensitivity in human muscle
PKC isoform activation has been proposed to mediate lipid-induced insulin resistance in muscle, liver and vas-
cular tissues [41,42]. We therefore assessed AMPKα1 Ser487 phosphorylation in muscle biopsy membrane frac-
tions we obtained in a previous study from European men in which the ISI had been assessed [37]. Muscle
microsomal AMPKα1 Ser487 phosphorylation showed a signiﬁcant inverse association with ISI (P < 0.05, r2 =
0.7337; Figure 8). Furthermore, individuals with an ISI of <7 exhibited signiﬁcantly higher levels of AMPKα1
Figure 5. Down-regulation of PKC prevents VEGF-stimulated Ser487 phosphorylation.
HUVECs were cultured for 20 h in the presence of 0.2 mmol/l PMA (cPMA) prior to stimulation with VEGF (10 ng/ml, 5 min),
AICAR (2 mmol/l, 45 min), A769662 (100 mmol/l, 60 min) or OAG (100 mmol/l, 20 min). Cell lysates were prepared and (A and B)
subjected to immunoblotting with the antibodies indicated or (C) AMPK activity was assayed. (A) Representative immunoblots
are shown, repeated on two further occasions with similar results. (B) Densitometric quantiﬁcation (mean ± SEM) of
immunoblots from three independent experiments. (C) Data represent mean ± SEM AMPK activity from three independent
experiments. **P < 0.01, *P < 0.05 relative to the absence of cPMA pre-treatment. $$$P < 0.001, $P < 0.05 relative to vehicle.
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Ser487 phosphorylation compared with those with an ISI of >7 (Figure 8). Phospho-MARCKS could not be
detected in any muscle biopsy sample (data not shown).
Discussion
The present study demonstrates that PKC isoforms stimulate AMPKα1 Ser487 phosphorylation, which is asso-
ciated with reduced AMPK activity. Furthermore, phosphorylation of AMPKα1 Ser487 exhibits a strong
inverse correlation with insulin sensitivity in human muscle. In addition, we demonstrate that an endogenous
AMPK activator, VEGF, stimulates both Ser487 and Thr172 phosphorylation concomitantly via distinct signal-
ling pathways in human endothelial cells.
Previous studies have demonstrated that Akt is an AMPKα1 Ser487 kinase that impairs activating Thr172
phosphorylation [13–15,17]. In contrast, this study demonstrates that VEGF-stimulated phosphorylation of
Figure 6. Overexpression of PKC increases basal Ser487 phosphorylation in HeLa cells and PKC is an in vitro AMPKα1
Ser487 kinase.
(A–C) HeLa cells were transfected with vectors containing bovine PKCα, human PKCβ1 or human PKCβ2, and cell lysates were
subjected to immunoblotting with the antibodies indicated. (A) Blots shown are representative of three independent
experiments in each case. (B and C) Quantiﬁcation (mean ± SEM) of AMPKα1 and ACC phosphorylation from three
independent experiments. (D and E) Dephosphorylated, immunoprecipitated myc-tagged kinase-dead AMPKα1 was
incubated in the presence of puriﬁed rat brain PKC or recombinant Akt1 (30 min, 30°C) as indicated in the presence or absence
of Ca2+ and PtdSer. Proteins were resolved by SDS–PAGE and analysed by immunoblotting with the antibodies indicated.
(D) Representative immunoblots from three independent experiments are shown. (E) Quantiﬁcation (mean ± SEM) of P-Ser487
relative to AMPKα1 from three independent experiments. *P < 0.05, ***P < 0.001 relative to the absence of kinase.
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AMPKα1 Ser487 is independent of Akt, using both Akti-1/2 and the PI3K inhibitor wortmannin. Furthermore,
Akt activation by insulin is not associated with increased AMPKα1 Ser487 phosphorylation in HUVECs. These
ﬁndings suggest that Akt activation alone is not sufﬁcient to stimulate Ser487 phosphorylation in human endo-
thelial cells, implying that Akt-mediated phosphorylation of this site is cell-speciﬁc and/or stimulus-speciﬁc.
Furthermore, ERK1/2 activation does not underlie VEGF-stimulated AMPKα1 Ser487 phosphorylation as this
was insensitive to an MEK1/2 inhibitor that ablated ERK1/2 phosphorylation.
AMPK autophosphorylation at Ser487/491 has been reported in vitro [13], yet STO-609 inhibited
VEGF-stimulated AMPK activity without inﬂuencing Ser487 phosphorylation, indicating that AMPK autopho-
sphorylation is unlikely to be the mechanism responsible. This is reinforced by the lack of effect of A769662 on
endothelial cell AMPKα1 Ser487 phosphorylation, despite robustly activating AMPK. Intriguingly, AICAR
Figure 7. Role of PKCm in VEGF-stimulated AMPKα1 Ser487 phosphorylation.
HAECs were pre-incubated in the presence or absence of 10 μmol/l CRT0066101 (CRT) for 1 h prior to stimulation with VEGF
(10 ng/ml, 5 min). Cell lysates were prepared, and (A–E) proteins were resolved by SDS–PAGE and immunoblotted with the
antibodies indicated or (F) AMPK was assayed. (A) Representative immunoblots are shown, repeated with similar results on
three further occasions. (B–E) Densitometric quantiﬁcation of immunoblots. Data are expressed as mean ± SEM relative to
VEGF-treated HAECs in the absence of inhibitor from four independent experiments. (F) AMPK activity (mean ± SEM) from
three independent experiments. †P < 0.05, ††P < 0.01, †††P < 0.001 relative to the absence of VEGF, *P < 0.05, ***P < 0.001
relative to the absence of CRT.
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stimulated AMPKα1 Ser487 phosphorylation in HAECs and HUVECs, as previously reported in neonatal rat
cardiomyocytes, VSMCs and a mouse microglial cell line [24–26]. In contrast, AICAR had no effect in HeLa
cells expressing LKB1, despite stimulating ACC phosphorylation. The mechanism by which AICAR stimulates
Ser487 phosphorylation in human endothelial cells is distinct from the mechanism of VEGF, as it was
unaffected by extracellular Ca2+ depletion or chronic PMA treatment. As AICAR stimulated AMPK activity in
both human endothelial cells and HeLa cells expressing LKB1, yet only stimulated AMPKα1 Ser487 phosphor-
ylation in endothelial cells, this also argues against autophosphorylation of AMPKα1 Ser487 being a major
mechanism in human cells. We have previously reported that AICAR stimulates Akt phosphorylation and
impairs ERK1/2 phosphorylation in HAECs [43], such that it remains possible that AICAR-stimulated Ser487
phosphorylation in human endothelial cells is mediated by Akt or an alternative AMPK-independent kinase.
The present study provides multiple lines of evidence that an isoform or isoforms of PKC phosphorylate
AMPKα1 Ser487. Puriﬁed rat brain PKC phosphorylates AMPKα1 Ser487 in vitro, with a similar efﬁciency to
the validated Ser487 kinase Akt. In addition, as the puriﬁed PKC is reported to consist primarily of PKCα, β and
γ isoforms with lesser amounts of δ and ζ isoforms, this suggests that the conventional PKC isoforms are capable
of phosphorylating AMPKα1 Ser487. Further evidence that conventional PKC isoforms phosphorylate AMPK is
that overexpression of either PKCα or PKCβ1 or incubation with the DAG mimetic PMA each stimulated
AMPKα1 Ser487 phosphorylation in HeLa cells. Similarly, both PMA and OAG stimulated AMPKα1 Ser487
phosphorylation in human endothelial cells. Furthermore, a physiological PKC activator, VEGF, stimulated
AMPKα1 Ser487 phosphorylation in a manner sensitive to (i) two different PKC inhibitors and (ii) down-
regulation of PKC by chronic PMA treatment. The sensitivity of VEGF-stimulated Ser487 phosphorylation to
LY333531 was identical with that of VEGF-stimulated phosphorylation of the PKC substrate MARCKS, further
providing evidence that Ser487 is a bona ﬁde substrate for PKC or a PKC-activated protein kinase. Despite this,
the sequence surrounding Ser487 in human AMPKα1 (PQRSGSVSNYRS) is not a conventional PKC consensus
phosphorylation site, suggesting that it may be part of a non-contiguous consensus motif [44].
Others have recently reported that the murine PKCm orthologue, PKD1, phosphorylates AMPKα2 in vitro
and is responsible for PMA-stimulated AMPKα2 Ser491 phosphorylation in a mouse myotube cell line [18]. In
the present study, PKCm inhibition did not signiﬁcantly attenuate VEGF-stimulated AMPKα1 Ser487 phos-
phorylation, indicating that PKCm cannot be the principal VEGF-stimulated AMPKα1 Ser487 kinase.
AMPKα2 is a minor catalytic isoform in human endothelial cells [43]. As neither PMA nor OAG stimulated
detectable AMPKα2 Ser491 phosphorylation, this suggests that human AMPKα2 Ser491 is not a PKC substrate
in endothelial cells and may be an autophosphorylation target, regulated independently of Ser487 as reported
recently [17]. The different results reported in this and the study of Coughlan and co-workers [18] may reﬂect
a species-speciﬁc role for PKCm/PKD1. Indeed, the PKCm inhibitor, CRT0066101, inhibited VEGF-stimulated
ACC phosphorylation without affecting AMPK activity in immunoprecipitates, suggesting stimulation of PKCm
is not associated with AMPK inactivation in human endothelial cells. The reason for the lack of effect of
CRT0066101 on AMPK activity while reducing VEGF-stimulated ACC phosphorylation is unclear. As the
AMPK assay is performed in saturating levels of AMP, the inhibitory effect of CRT0066101 on ACC
Figure 8. AMPKα1 Ser487 phosphorylation is inversely related to insulin sensitivity in human muscle.
Human muscle biopsy membrane fractions were prepared in a previous study [35] and stored at −80°C. (A) Membrane fraction
proteins of individuals of the indicated ISI were resolved by SDS–PAGE and immunoblotted using the antibodies shown.
(B) Quantiﬁcation (mean ± SEM) of AMPKα1 Ser487 phosphorylation relative to total AMPKα. *P < 0.05 comparing individuals
with an ISI of <7 with those with an ISI of >7.
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phosphorylation may reﬂect an inhibition of allosteric activation of AMPK or alternatively an off-target effect
on ACC itself, increased ACC dephosphorylation or prevention of ACC phosphorylation by AMPK.
Phosphorylation of AMPKα1/α2 at Ser487/491 has been reported to inhibit AMPK activity [12–18]. This is
supported by the present study, in which PMA stimulation of endothelial cells inhibited basal AMPK activity
and attenuated AICAR-stimulated ACC phosphorylation in HeLa cells overexpressing LKB1. As the inhibition of
AMPK activity by PMA was not observed in AMPK KO MEFs expressing mutant AMPKα1 Ser487Ala, it is
highly likely that the inhibition of AMPK activity by PKC activators is due to Ser487 phosphorylation, although
we cannot rule out that the effect of PMA is mediated by a Ser487 kinase other than PKC. Furthermore, incuba-
tion of HAECs with either of the two PKC inhibitors GF109203X or LY333531 stimulated basal AMPK activity.
This is in agreement with a previous study, in which PMA decreased AMPK activity in a GF109203X-sensitive
manner in rat cardiac myocytes [45]. Furthermore, GF109203X and another PKC inhibitor Ro-31–8425 have
been reported to increase AMPKα Thr172 phosphorylation in mouse primary hepatocytes [46], and vinorelbine
has been reported to stimulate PKC with concomitant inhibition of AMPK in HUVECs [47]. The present study
extends these observations, demonstrating a clear inhibitory role for PKC isoforms in the regulation of AMPK
inhibitory phosphorylation. In contrast with these and the present study, AMPK activation by preconditioning
with ischaemia–reperfusion in rabbit myocardium has been reported to be attenuated by intravenous administra-
tion of GF109203X for 5 min [48], arguing that PKC inhibition is associated with reduced AMPK activity.
Furthermore, PMA has been reported to rapidly stimulate AMPKα Thr172 phosphorylation in a
GF109203X-dependent manner in THP-1 cells, such that PKC has been proposed to be upstream of LKB1 and
AMPK [49]. The reasons for these discrepancies may be due to cell-speciﬁc actions of PKC or off-target effects
of the reagents used, yet neither GF109203X nor LY333531 had any effect on immunoprecipitated human endo-
thelial cell AMPK activity in vitro, suggesting that they do not directly stimulate AMPK.
Despite a weight of evidence supporting a role for PKC in directly phosphorylating AMPKα1 on Ser487, the
nature of the PKC isoform responsible for VEGF-stimulated AMPKα1 Ser487 phosphorylation remains elusive.
Although VEGF-stimulated AMPKα1 Ser487 phosphorylation was inhibited by the conventional (α, β1, β2 and
γ) PKC isoform-selective inhibitor GF109203X, this may inhibit several other kinases in cell-free assays [50].
The PKCβ-selective inhibitor LY333531 has, however, been reported to exhibit much greater speciﬁcity [50]
and did not inﬂuence AMPK activity directly in cell-free assays, but impaired VEGF-stimulated AMPKα1
Ser487 phosphorylation with identical kinetics to VEGF-stimulated MARCKS phosphorylation. Overexpression
of PKCα or PKCβ1 was sufﬁcient to cause a modest increase in AMPKα1 Ser487 phosphorylation in HeLa
cells, yet down-regulation of PKCα (or PKCμ) had no effect on VEGF-stimulated AMPKα1 Ser487 phosphor-
ylation in HUVECs. As VEGF-stimulated AMPKα1 Ser487 phosphorylation is mimicked by OAG and inhib-
ited by LY333531 and chronic PMA incubation, it is likely that a DAG-stimulated PKC sensitive to both
LY333531 and chronic PMA is responsible. It remains possible, therefore, that PKCγ, η or θ is responsible for
the actions of VEGF, or that there is signiﬁcant redundancy between PKC isoforms in their capacity to phos-
phorylate AMPKα1 Ser487.
PKC activation has been proposed to underlie lipid-induced insulin resistance in muscle, liver and vascular
tissues [41,42], such that increased PKC-mediated inhibitory phosphorylation of AMPKα might explain reduced
AMPK activity. In rodents, increased AMPKα1 Ser487 phosphorylation has been reported in brains and aortae
from obese and diabetic mouse models, with concomitant increased basal phosphorylation of Akt [15,51],
whereas increased AMPKα1/α2 Ser487/491 phosphorylation has been observed in muscles from glucose-infused
rats [27]. In humans, infusion of glucose in healthy volunteers after sprinting increased phosphorylation of
Ser487/491 in human vastus lateralis muscle, as assessed with an antibody that recognises both phosphorylated
species [52]. We demonstrate a strong inverse relationship between insulin sensitivity and AMPKα1 Ser487
phosphorylation in vastus lateralis muscle from insulin-sensitive individuals. Ser487 phosphorylation in these
muscle samples does not correlate with the phospho-Akt levels we have reported previously [37], such that it
remains possible that PKC mediates Ser487 phosphorylation, although we were unable to detect any
phospho-MARCKS as a surrogate of PKC activity. AMPKα1 is the minor catalytic subunit isoform in murine
muscle, yet complexes containing AMPKα1 have been reported to contribute ∼50% of the basal AMPK activity
in human vastus lateralis muscle [53], suggesting that increased Ser487 phosphorylation may markedly inﬂuence
human muscle AMPK activity. We cannot, however, exclude the possibility that the AMPKα1 Ser487 phosphor-
ylation observed in the present study is associated with vascular cells or leukocytes within the muscle.
Taken together, these data indicate that PKC is an AMPKα1 Ser487 kinase, which reduces AMPK activity.
As PKC can be activated by lipid metabolites formed in metabolic tissues as a consequence of overnutrition, it
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can be speculated that PKC-mediated phosphorylation of AMPKα1 Ser487 underlies the reduced AMPK activ-
ity observed in tissues from mouse models of overnutrition and insulin-resistant people. It remains to be char-
acterised whether the functional consequences of Ser487-mediated AMPK inactivation contribute to the
pathogenesis of insulin resistance, dysfunctional metabolism and their associated cardiovascular complications.
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